OCS

NASD Oculis Holding AG

Oct 31, 2026 · 4:55 AM ET EOD Market Closed

$8.26 ↑ +0.00 (+0.00%) Trading Up from the previous close of $8.26, $0.58 below the day’s high of $8.84

YTD change: -58.64%
vs 20-day SMA: +3.54%
vs 200-day SMA: -56.29%

Price ranges

Previous day

$8.19 $8.84

open $8.19 close $8.26

+$0.07 (+0.85%)

Today

$8.19 $8.84

$8.26

Past week

$7.65 $8.53

from $8.09 now $8.26

+$0.17 (+2.10%)

Past month

$7.11 $9.00

from $8.76 now $8.26

-$0.50 (-5.71%)

This year

$7.11 $34.48

from $19.97 now $8.26

-$11.71 (-58.64%)

Price & Performance

-19.22 (-69.94%) / 6M

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Neutral

The stock is 76.0% away from all-time highs of $34.48
OCS is down 59% since the beginning of the year
OCS is down 59% over the past 12 months
OCS is down 6% over the past 1 month
3% of all OCS investors are betting against OCS

OCS reads neutral: price sits above one of the two key moving averages, the 12-month move is -57.2%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No

EPS $-0.197934

Earnings momentum +59.3% Quarterly EPS growth

Quarterly change +59.3%

Valuation

P/E ratio N/A

Enterprise value $225.0M

Beta 0.48

Balance sheet & scale

IncomeN/A

RevenueN/A

Cash$283.1M

Debt$3.2K

Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD

Sector Manufacturing

Sub Sector Chemical Manufacturing

Market cap $561.2M

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Competitor comparison

Ticker	Company	Price	Change
LLY	Eli Lilly and Company	$1,417.54	+3.19%
JNJ	Johnson & Johnson	$273.20	-0.73%
ABBV	AbbVie, Inc.	$294.89	+1.41%
MRK	Merck & Co., Inc.	$149.52	+2.18%
RHHBY	Roche Holding Ltd Sponsored ADR	$61.27	+0.82%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.